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The Role of the Sodium-Taurocholate Cotransporting
Polypeptide (NTCP) and of the Bile Salt Export Pump (BSEP) in
Physiology and Pathophysiology of Bile Formation
Abstract
Bile formation is an important function of the liver. Bile salts are a major constituent of bile and are
secreted by hepatocytes into bile and delivered into the small intestine, where they assist in fat digestion.
In the small intestine, bile salts are almost quantitatively reclaimed and transported back via the portal
circulation to the liver. In the liver, hepatocytes take up bile salts and secrete them again into bile for
ongoing enterohepatic circulation. Uptake of bile salts into hepatocytes occurs largely in a
sodium-dependent manner by the sodium taurocholate cotransporting polypeptide NTCP. The transport
properties of NTCP have been extensively characterized. It is an electrogenic member of the solute
carrier family of transporters (SLC10A1) and transports predominantly bile salts and sulfated
compounds, but is also able to mediate transport of additional substrates, such as thyroid hormones,
drugs and toxins. It is highly regulated under physiologic and pathophysiologic conditions. Regulation
of NTCP copes with changes of bile salt load to hepatocytes and prevents entry of cytotoxic bile salts
during liver disease. Canalicular export of bile salts is mediated by the ATP-binding cassette transporter
bile salt export pump BSEP (ABCB11). BSEP constitutes the rate limiting step of hepatocellular bile
salt transport and drives enterohepatic circulation of bile salts. It is extensively regulated to keep
intracellular bile salt levels low under normal and pathophysiologic situations. Mutations in the BSEP
gene lead to severe progressive familial intrahepatic cholestasis. The substrates of BSEP are practically
restricted to bile salts and their metabolites. It is, however, subject to inhibition by endogenous
metabolites or by drugs. A sustained inhibition will lead to acquired cholestasis, which can end in liver
injury.
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Abstract 
Bile formation is an important function of the liver. Bile salts are a major constituent of bile 
and are secreted by hepatocytes into bile and delivered into the small intestine, where they 
assist in fat digestion. In the small intestine, bile salts are almost quantitative reclaimed and 
transported back via the portal circulation to the liver. In the liver, hepatocytes take up bile 
salts and secrete them again into bile for ongoing enterohepatic circulation. Uptake of bile 
salts into hepatocytes occurs largely in a sodium-dependent manner by the sodium 
taurocholate cotransporting polypeptide NTCP. The transport properties of NTCP have been 
extensively characterized. It is an electrogenic member of the solute carrier family of 
transporters (SLC10A1) and transports predominantly bile salts and sulfated compounds, but 
is also able to mediate transport of additional substrates such as for example thyroid hormones, 
drugs and toxins. It is extensively regulated under physiologic and pathophysiologic 
conditions. Regulation of NTCP copes with changes of bile salt load to hepatocytes and 
prevents entry of cytotoxic bile salts during liver disease. Canalicular export of bile salts is 
mediated by the ATP-binding cassette transporter bile salt export pump BSEP (ABCB11). 
BSEP constitutes the rate limiting step of hepatocellular bile salt transport and drives 
enterohepatic circulation of bile salts. It is extensively regulated to keep intracellular bile salt 
levels low under normal and pathophysiologic situations. Mutations in the BSEP gene lead to 
severe progressive familial intrahepatic cholestasis. The substrates of BSEP are practically 
restricted to bile salts and their metabolites. It is however subject to inhibition by endogenous 
metabolites or by drugs. A sustained inhibition will lead to acquired cholestasis, which can 
end in liver injury. 
 
Key words: bile salt transporter, bile formation, cholestasis 
 
1. Physiology of Bile Formation 
 
Bile production is one of the key functions of the liver. Bile is delivered from the liver to the 
small intestine, where it is indispensable for the absorption of lipids and of fat soluble 
vitamins. Lipids are an essential part of our diet and constitute an important energy source for 
the body. Fat soluble vitamins are vital for many processes, e.g. vitamin K deficiency leads to 
a disturbed balance of the blood clotting system. Hence, ongoing bile formation by the liver 
and undisturbed bile flow are vital processes to satisfy the energy needs of our body as well as 
to provide essential food constituents to our body. Major constituents of the bile fluid are bile 
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salts, phospholipids and organic anions [70]. Bile salts are amphipathic molecules, display 
detergent properties and form together with the phospholipids mixed micelles [130, 131]. The 
mixed micelles reduce the detergent action and consequently the toxicity of bile salts in bile 
[319] and act in addition as carriers for the biliary elimination of poorly water soluble 
substances, e.g. cholesterol. If bile salts accumulate within hepatocytes, they impair 
mitochondrial function and hence are cytotoxic [169, 277]. 
 
Bile salts are synthesized from cholesterol in hepatocytes by a complex biosynthetic process 
comprising 17 reactions catalyzed by 16 different enzymes [264]. Bile salt biosynthesis 
constitutes the major catabolic pathway of cholesterol. Bile salts are secreted from 
hepatocytes into the canaliculi, from where they flow via the biliary tree into the gall bladder 
(except in species, which have none) [130, 131]. From the gall bladder, bile salts are released 
with bile into the duodenum where they promote further digestion of the chyme, in particular 
the absorption of fat. Along the small intestine, bile salts are absorbed by more than 90 % 
both passively and actively and are transported back to the liver via the portal circulation. In 
the liver, bile salts are taken up into hepatocytes, from where they are secreted again into bile 
[8, 57, 131, 165, 180, 215, 251, 253]. This circling of bile salts between the liver and the 
small intestine is called enterohepatic circulation. Overall, the total bile salt pool of humans (3 
to 4 g) circulates per day 6 to 10 times between the liver and the small intestine, whereby only 
about 0.5 g of bile salts are not reclaimed, but lost instead via fecal excretion [129]. Hence, 
enterohepatic circulation is a very efficient process. The size of the bile salt pool is monitored 
in the enterocytes of the ileum, where the expression of the nuclear transcription factor FXR 
positively correlates with bile salt load. FXR in turn regulates the transcription of FGF15 (in 
rodents, FGF19 in man). FGF15 is secreted into the portal circulation and in the liver 
represses via a receptor mediated process the biosynthesis of bile salts [55, 258]. In humans, 
reduced serum levels of FGF19 lead to bile salt induced diarrhea, which highlights the 
importance of a tight control of the bile salt pool [132, 335]. In addition to its tight regulation, 
bile acid biosynthesis undergoes diurnal variation, as exemplified by a diurnal rhythm of 
biliary bile salt and lipid secretion [234]. In mice, disruption of the clock genes Per1 and Per2 
leads to an impaired bile salt homeostasis with elevated serum bile salt levels [203]. 
 
Hepatocellular bile salt secretion requires the coordinate action of distinct transporters located 
in the sinusoidal and in the canalicular membrane of hepatocytes [180, 215]. In the basolateral 
hepatocyte membrane, uptake of bile salts occurs predominantly in a sodium-dependent 
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manner via the sodium taurocholate cotransporting polypeptide (Ntcp in rodents, NTCP in 
humans, gene symbol Slc10a1 in rodents, SLC10A1 in humans) and to a minor extent in a 
sodium-independent manner mediated by organic anion transporting polypeptides (Oatps in 
rodents, OATPs in humans , gene symbol Slco in rodents, SLCO in humans) [215]. Transport 
across hepatocytes is a fast process: In rats, after injection of an intravenous bolus, 
taurocholate appears in bile in much less than a one minute and the bolus is almost completely 
recovered in bile within ten minutes after injection [51]. The pathway across hepatocytes is 
not yet fully understood and different mechanisms may step in depending on the bile salt load 
imposed to hepatocytes. At a physiologic exposition, the monomeric form of bile salts in the 
cytoplasm is likely < 1 μM [344]. Part of the bile salts are bound to cytoplasmic bile salt 
binding proteins, e.g. 3α-hydroxysteroid dehydrogenase, glutathione-S-transferase, rat liver 
fatty acid binding protein and human bile salt binding protein [4, 299]. These proteins may 
mediate bile salt diffusion from the basolateral to the apical membrane along an intracellular 
concentration gradient. Under a high bile salt load, bile salts partition due to their 
hydrophobicity into intracellular membranes and vesicles [69, 184, 281, 303]. In this 
condition a transcellular vesicular transport route becomes relevant [51], which however 
under normal physiologic conditions seems not to play an important role [4, 50]. The issue of 
vesicular bile salt transport is complicated by the fact that bile salts regulate microtubule 
function, which provide tracks for vesicle movement and are important to regulate carrier 
density in the canalicular membrane [67, 211]. Furthermore, several Rab-proteins can bind 
lithocholate [138] and hence also modulate vesicular trafficking within hepatocytes. Bile salt 
secretion across the canalicular membrane is known to be the rate limiting step of 
hepatocellular bile salt secretion [260], is an ATP-dependent process [3, 233, 237, 297] and is 
mediated by an ATP-binding cassette (ABC) transporter named bile salt export pump (Bsep in 
rodents, BSEP in humans, gene symbol Abcb11 in rodents, ABCB11 in humans) [94, 180, 
215, 291, 296]. Hence, due to its strategic location in the enterohepatic bile salt circulation, 
BSEP drives and maintains enterohepatic circulation of bile salts. 
 
Disturbed bile formation leads to a reduction of bile flow and is called cholestasis. Cholestasis 
will lead to retention of bile salts within hepatocytes. The accumulated bile salts will, as a 
consequence of their detergent properties, induce damage to mitochondria and consequently 
become cytotoxic to hepatocytes [169, 287]. If cholestasis persists, the liver will be damaged 
and serum bile salts will raise followed by an increase of plasma liver enzymes as a 
consequence of liver injury. In order to lower or prevent the toxicity of the retained bile salts, 
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they are detoxified by sulfation [7]. An additional protective mechanism is down-regulation of 
bile salt uptake systems as well as up-regulation of salvage transport systems [92, 332]. 
 
2. The sodium  taurocholate cotransporting polypeptide Ntcp/NTCP 
 
2.1. Molecular Properties 
 
The first Ntcp orthologue to be molecularly identified was cloned from rat liver using the 
Xenopus laevis expression cloning methodology [107]. Ntcp/NTCP was subsequently cloned 
from many species including human [105], mouse [38] and rabbit [170] and additional 
orthologues are predicted in the genomes of a variety of species [96]. Rat Ntcp is the founding 
member of the of the solute carrier family [117] number 10 (SLC10) of transporters [103]. 
The SLC10 is comprised of 7 members, 3 of which have been functionally characterized and 
4 orphan transporters. The characterized transporters include Ntcp, the apical sodium bile acid 
transporter (ASBT; SLC10A2) and the steroid sulfate transporter (SOAT; SLC10A6) [57, 96]. 
The human and rat NTCP genes span 21.4 and 13.6 kb, map to chromosomes 6q24 and 14q24 
and encode 349 and 362 amino acids, respectively [48, 105]. Mouse Ntcp covers 12.5 kb, is 
found on chromosome 12qD1 and is transcribed into two variants, which differ at their C-
terminus [38, 97]. The predicted molecular weight of rat Ntcp is about 39 kDa and in silico 
hydropathy analysis predicted 7 transmembrane spanning domains and five putative N-linked 
glycosylation sites [107]. Expression of Ntcp in X. laevis oocytes demonstrated a glycosylated 
protein with an apparent MW of ~35 kDa after enzymatic deglycosylation. Ntcp glycosylation 
was confirmed by in vitro translation in a reticulocyte lysate system yielding an apparent MW 
for the unglycosylated form of ~33 kDa. In vitro translation studies using a reticulocyte lysate 
system showed no evidence of a cleaved signal sequence in agreement with in silico analysis 
[107]. N-linked glycosylation was experimentally confirmed in basolateral plasma 
membranes from rat hepatocytes [9, 294]. The C-terminus of Ntcp was immunologically 
localized to the intracellular side of the plasma membrane and the native molecular weight in 
rat liver was determined as 51 kDa [9, 294]. Site directed mutagenesis experiments with the 
rat orthologue demonstrated the first two putative N-linked glycosylation sites to be 
glycosylated, confirming that the N-terminus is extracellular. [102]. Additional 
posttranslational modifications of Ntcp include phosphorylation [231, 232] and ubiquitination 
[174]. 
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The structure of Ntcp has not yet been resolved, but experimental evidence derived from 
translation/insertion scanning, alanine insertion scanning and mutation of putative N-linked 
glycosylation site provides evidence for nine transmembrane spanning domains [108], which 
was later refined to seven transmembrane spanning domains and helices 7 and 8 forming an 
extracellular loop at the plasma membrane. This loop is essential for function [207]. Using 
site directed mutagenesis in conjunction with expression in X. laevis oocytes [349] or COS-7 
cells [267], Asp115, Glu257, Cys266 and Cys96, Cys250, Cys266 were found to be 
functionally essential for rat and mouse Ntcp, respectively. 
 
2.2. Subcellular expression and tissue distribution 
 
Immunofluorescence experiments localized Ntcp to the basolateral plasma membrane of rat [9, 
294] and human hepatocytes [177]. It displays an even expression throughout the liver acinus. 
Next to the liver, northern blot analysis also indicated expression of Ntcp in rat kidney [107], 
which so far has not been confirmed at the protein level. Later, expression of Ntcp was 
observed in the luminal membrane of pancreatic acinar cells [152]. An additional organ, 
which is involved in bile salt transport is the placenta, where a fetal to maternal bile salt 
gradient exists [204]. While in the human placenta NTCP has reported to be absent [209, 246], 
low levels of Ntcp mRNA have been reported for rat placenta [191, 289]. 
 
2.3. Phylogenetics and ontogenesis 
 
The phylogenetic analysis of Ntcp revealed that Ntcp is only found in mammalian species, but 
not in other vertebrates such as chicken, turtle, frog or skate [29]. The ontogeny of Ntcp 
parallels the development of the bile salt pool [198, 305] and first mRNA expression is seen 
around day 18 of gestation in rats [29, 289] with protein clearly detectable the basolateral 
plasma membrane of embryonic hepatocytes at day 20 of gestation [85]. Complete 
glycosylation of the protein is only observed about 4 weeks after birth [109]. Functionally, 
sodium-dependent bile salt transport is observed at day 20 of gestation [304] coinciding with 
the first basolateral protein expression of Ntcp in fetal liver. This relatively late appearance of 
Ntcp during ontogenesis is reproduced in primary cultures of small hepatocytes, which 
expand and differentiate into mature hepatocytes [243, 280]. Small hepatocytes are hepatocyte 
progenitor cells found in adult liver [44]. In primary cultured rat hepatocytes, Ntcp is rapidly 
down-regulated at the mRNA and at the protein level [195, 261]. Therefore, Ntcp might serve 
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as a very sensitive marker for monitoring the degree for the differentiation state of primary 
cultured hepatocytes. 
 
2.4. Transport properties 
 
Functional characterization of Ntcp requires its expression in heterologous expression systems. 
The membrane environment, e.g. via cholesterol content, may influence transporter activity, 
as for example recently demonstrated for Ntcp expressed in HEK-293 cells [226], a careful 
comparison of the characteristics of Ntcp delineated in heterologous expression systems with 
results obtained from studies in its "natural" environment, e.g. from perfused liver, isolated 
hepatocytes or subcellular fractions is warranted. While normal physiologic expression levels 
of Ntcp may vary between species and certainly vary between different expression systems, 
the affinity of Ntcp for its substrates as reflected by the Km value should remain constant. A 
comparison of Km values for hepatic and Ntcp/NTCP-mediated sodium-dependent 
taurocholate transport is provided in table 1. Comparison of the properties of the cloned 
protein with physiologic parameters determined in organ or cellular systems is feasible for rat 
Ntcp, as a vast literature exists on hepatic handling of bile salts by rats. It is evident from table 
1 that the Km value of the cloned rat Ntcp matches very well the Km values determined in the 
perfused rat liver, in isolated rat hepatocytes and in isolated liver plasma membrane vesicles. 
These results strongly support the prevailing concept that the Ntcp is the physiologically 
relevant sodium-dependent taurocholate (and bile salt) uptake system in rat liver. This 
conclusion is also supported by results from a study combining an antisense oligonucleotide 
approach with expression of total mRNA from rat liver in X. laevis oocytes. In this study, 
coexpression of antisense oligonucleotides against rat Ntcp with total rat liver mRNA lead to 
a complete knock-down of sodium-dependent bile salt uptake into the oocytes [106]. This is 
evidence that Ntcp is the only sodium-dependent bile salt uptake system in rat liver. While 
Ntcp appears to account for most, if not all hepatic Na+-dependent bile salt transport, the 
presence of additional sinusoidal Na+-dependent bile salt transporters has been suggested. The 
microsomal epoxide hydrolase has been postulated as an additional basolateral, sodium-
dependent bile salt uptake system [328], albeit with conflicting and equivocal evidence [133, 
214]. Mice with a disrupted gene for microsomal epoxide hydrolase were reported to be 
phenotypically normal [224], which may be taken as evidence that these mice had no obvious 
defect in bile salt homeostasis. A patient with high serum bile salt levels was described as 
having no apparent irregularities in the NTCP gene and its expression, but a mutation in the 
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promoter of microsomal epoxide hydrolase. This mutation results in a marked reduction of the 
activity of this promoter in vitro and a pronounced reduction of microsomal epoxide 
hydrolase protein as assessed by Western blotting in liver tissue from this patient [352]. As to 
date no Ntcp null mice have been described, the role of microsomal expoxide hydrolase 
cannot be settled on grounds of genetic evidence. The data on rat Ntcp given in table 1 are 
also strong evidence that the different expression systems seem to have only a minimal 
influence on the affinity of this transporter for taurocholate. The published Km values for 
sodium-dependent taurocholate transport into human hepatocytes vary considerably (table 1). 
A likely explanation for this finding are differences in procurement of human liver tissue 
samples and differences of the physiologic state of the donor tissue. Nevertheless, cloned 
human NTCP expressed in heterologous systems (table 1) suggest a rather high affinity for 
the human transporter towards taurocholate. 
 
Ntcp transports two sodium ions together with one bile salt molecule [106], which makes it an 
electrogenic transporter [343]. It therefore functions as a secondary active transporter and 
utilizes as driving force both, the out to in sodium gradient maintained by the (Na+K)-ATPase 
localized in the basolateral plasma membrane of hepatocytes and the inside negative 
membrane potential of about -35 mV to -40 mV, which is governed mainly by ion channels 
[28, 76]. Hence, the energetics allows Ntcp to take up bile salts from the portal blood against 
a concentration gradient into hepatocytes. In transport experiments using isolated basolateral 
plasma membrane vesicles, albumin stimulates sodium-dependent taurocholate uptake by 
lowering the Km value [20, 353]. Expression of total mRNA from rat liver in X. laevis oocytes 
followed by determination of sodium dependent taurocholate transport in the presence of 
albumin also results in a stimulation of the transport activity by low concentrations of albumin 
[104]. This indicates that transport activity of rat Ntcp may be directly stimulated by albumin. 
This assumption was confirmed for human NTCP expressed in CHO cells [153]. 
 
Addition of EGFP to the C-terminus of Ntcp did not affect the targeting to the plasma 
membrane inHepG2 cells nor did it affect the Km value of Ntcp [178], demonstrating that a 
free C-terminus is not essential for function. Similar results were obtained for human NTCP 
[307]. Deleting the 56 amino acid C-terminus of rat Ntcp did not abolish its transport function 
(Km for the truncated form: of 44 μM; for wild type: 30 μM), but severely impaired its plasma 
membrane targeting in COS-7 and MDCK cells [306]. This demonstrates that the C-terminus 
of Ntcp is important for efficient plasma membrane targeting. 
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The substrate specificity the cloned Ntcps has been studied to a great extent and has been 
covered and compared with data from in vivo systems in many reviews [8, 57, 96, 179, 180, 
214, 215, 309, 318]. Table 2 gives an overview on these findings by listing Ntcp substrates 
different from taurocholate. Ntcp has a preference for glycine and taurine conjugated bile salts 
over their unconjugated counterparts. Additionally, the affinity is often higher for dihydroxy 
bile salts (conjugates of chenodeoxycholate and deoxycholate) than for trihydroxy bile salts 
(conjugates of cholate). Besides different bile salts, estrone-3-sulfate and bromosulfophthalein 
are good substrates. Ntcp is also able to transport drugs conjugated to bile salts and hence is a 
potential drug target [208, 323]. Thyroid hormones and their metabolites are additional 
substrates of Ntcp [80, 327]. Of note, human NTCP is able to mediate transport of 
rosuvastatin and accounts for about 35 % of total rosuvastatin uptake into isolated human 
hepatocytes [126]. For high throughput experiments with a transporter, fluorescent molecules 
are desirable. For potential application of such screenings to Ntcp, the following fluorescent 
bile salts have been shown to be substrates with heterologously expressed Ntcp: 
cholylglycylfluorescein and chenodeoxycholyllysyl-NBD [30], NBD-cholyltaurine [257] and 
cholylglycylamidofluorescein and chenodeoxycholylglycylamidofluorescein [221], but not 
cholyl-L-lysyl-fluorescein [58]. This latter finding highlights the importance of the side chain 
a determinant for Ntcp substrates [17]. 
 
2.5. Ntcp inhibitors 
 
The liver is a major site for drug metabolism and elimination, particularly for poorly water 
soluble drugs. As bile salts are also amphipathic molecules, Ntcp is subject to inhibition by 
various drugs. For example, the immunosuppressant cyclosporine leads to cholestatic liver 
injury [13]. Cyclosporine inhibits sodium-dependent taurocholate uptake into isolated rat 
[290] and human hepatocytes [16] as well as into isolated rat basolateral plasma membrane 
vesicles [227, 353]. Cyclosporine clearly inhibits rat Ntcp [273] and human NTCP [221] in 
heterologous expression systems, with an IC50 value of 1 μM [153]. However, it is not 
transported by rat Ntcp expressed in X. laevis oocytes [273]. Similar results were obtained for 
bumetanide, which is also inhibitor but not a transport substrate for rat Ntcp [257, 273]. 
Consequently and importantly, inhibition experiments should not be used with transporters as 
stand alone assays to identify transported substrates. Rat Ntcp is also inhibited by probenicide 
[257]. Inhibition of Ntcp should lead to an increase of serum bile salt levels, but the effects 
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may be variable. The liver also expresses sodium-independent bile salt transporters, namely 
the organic anion transporting polypeptides (OATPs), which may partially compensate for the 
inhibition of NTCP. However, it should be noted that these compounds can often inhibit 
OATPs in addition to NTCP, as demonstrated for rifampicin and rifamycin with rat Ntcp, 
Oatp1a1 and Oatp1a4 [71] and for cyclosporine with NTCP, OATP1B1 and OATP1B3 [321]. 
This inhibition of sodium-dependent and sodium-independent bile salt uptake into 
hepatocytes is predicted to increase serum bile salt levels, depending in part on the relative 
affinities of the inhibitors to the different transporters [71]. Such an inhibition could diminish 
intracellular bile salt concentrations in hepatocytes and consequently lower the cytotoxic 
action of bile salts. This concept has so far not been tested experimentally. Examples of other 
drugs reported to inhibit NTCP are: (R)-propanolol (IC50 6 μM), (S)-propanolol (IC50 6 μΜ), 
furosemide (IC50 15 μM), ketokonazole (264 μM), renin inhibitors and a somatostatin 
analogue [153], rifamycin SV and glibenclamide [221], the antiviral drugs ritonavir (IC50 2 
μM), saquinavir (IC50 7 μM) and efavirenz (IC50 43 μM) [213] or bosentan (IC50 24 μM) 
[194]. 
 
2.6. Pathophysiology 
 
Currently, no human diseases caused by mutations in the NTCP gene are known, even though 
patients with primary hypercholanemia have been described [37, 278]. Information regarding 
changes for NTCP expression in liver disease is limited and frequently based on cholestatic 
liver diseases. In liver samples obtained from patients with progressive familial intrahepatic 
cholestasis, NTCP was down regulated at the protein, but not at the mRNA level, indicating a 
posttranslational regulation of NTCP in this disease [148]. As a consequence of progressing 
obstructive cholestasis, such as for example in biliary atresia, NTCP is down regulated at the 
mRNA level [42, 278]. The mRNA level of NTCP correlates inversely with serum bilirubin 
and serum bile salt levels, respectively [278, 358]. Restoration of bile flow in such patients 
increased mRNA levels for NTCP [278]. In patients with chronic hepatitis C or primary 
biliary cirrhosis stage I and II, no change in NTCP expression was observed [161, 357, 358], 
while in stage III it was down regulated [161]. If inflammation was the cause of cholestasis, 
NTCP was markedly down regulated [358], which is reproduced at the mRNA and protein 
level in primary cultured human liver slices treated with LPS [68] or in isolated and cultured 
human hepatocytes treated with IL-1β, tumor necrosis factor α or IL-6 [188, 190]. In 
hepatocellular carcinoma, NTCP is down regulated in comparison to the surrounding healthy 
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tissue [177, 359]. Complementing this finding, NCTP expression is absent in the hepatoma 
cell line HepG2 [176, 189]. In summary, in human liver disease, NTCP expression is often 
down regulated. This can be considered to be a protective adaptation as down-regulation of 
NTCP should lower the load of potentially cytotoxic bile salts for hepatocytes. Liver 
transplantation involves a period of ischemic stress for the transplanted organ. It was found 
that after liver transplantation NTCP mRNA is increased significantly [95]. 
 
Animal models of cholestasis have reproduced the human pattern of NTCP expression during 
liver disease and exhibit down-regulation of Ntcp after bile duct ligation, which is more 
pronounced in the periportal areas [63], treatment with ethinylestradiol or administration of 
LPS [66, 86, 98, 228, 282, 283]. In rats treated with trinitrobenzene sulfonic acid, an animal 
model of primary sclerosing cholangitis, Ntcp was transiently down regulated at the mRNA 
and protein level [89]. If animals were treated with a heat shock (42 °C body temperature for 
10 min.) 2 hrs prior to the application of LPS, down-regulation of Ntcp was prevented by a 
posttranslational mechanism [24]. The expression of Ntcp in animal models of liver disease is 
affected by hepatocellular retention of bile salts, but not by variations of transcellular bile salt 
flux [87, 164, 345]. CCl4 treatment of rats as a model for toxic liver injury leads to a marked 
down regulation of Ntcp mRNA and protein [90, 91], while no change in obese Zucker rats is 
seen [245]. In a model of fatty liver, the ob/ob mouse, Ntcp protein is down regulated in both 
males and females, but Ntcp mRNA is down regulated only in female mice [46]. Hypoxic 
liver injury after ischemia in rats and mice leads to a down-regulation of Ntcp at the mRNA 
and protein level [78, 128]. This is also observed for cold ischemic injury in conjunction with 
liver transplantation in Mdr2+/- mice used as a model for bile duct injury [127]. Ntcp has also 
been shown to be down regulated in pregnancy [14], though this has not been a universal 
finding [36]. After delivery, the expression of Ntcp is increased [36, 84]. Finally, in the 
regenerating rat liver, Ntcp is transiently down regulated both at the mRNA, protein and 
functional level [64, 93, 99, 331]. 
 
The expression of Ntcp is not only modulated in various pathophysiologic situations as 
outlined above, but its expression in the basolateral hepatocyte membrane is also subject to 
regulation by posttranslational modification through phosphorylation/dephosphorylation [11]. 
cAMP, but not cGMP stimulates basolateral taurocholate transport and increases Ntcp by 
translocating it into basolateral membrane [230]. This process is independent of microtubules. 
Ntcp is phosphorylated at serine and threonine residues and the dephosphorylation of these 
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residues is stimulated in a cAMP-dependent way [231], which consequently leads to 
incorporation of dephosphorylated Ntcp into the basolateral membrane. The intracellular pool 
of the phosphorylated form resides in an endosomal compartment for recruitment to the 
basolateral membrane [232]. The translocation of Ntcp to the basolateral plasma membrane is 
facilitated in HuH cells expressing Ntcp by activation of Rab4 [272]. 
 
2.7. Pharmacogenomis 
 
In 48 Japanese individuals, 14 single nucleotide polymorphisms were identified in the NTCP 
gene [269] and 4 insertion/deletion polymorphisms. Two of the polymorphisms were found in 
exons, namely p.T75T (c.307G>A) in exon 1 and p.S267F in exon 4. No variants were 
observed in the promoter region of the NTCP gene and the functional consequences of the 
alterations were not investigated. Screening of a cohort of 50 European Americans, 50 
African Americans and 50 Chinese Americans identified several polymorphisms, 4 of which 
were nonsynonymous (c.668T>C (p.S267F), c.800C>T (p.S267F), c.836T>C (p.I279T) and 
c.940A>G (p.K314E) [125]. All these variants were expressed in HeLa cells and functionally 
compared to NTCP*1 for their transport properties with taurocholate, cholate and estrone-3-
sulfate as substrates. With the exception of the p.I223T variant, the others displayed 
significant cell surface expression. Of all variants, p.S267F displayed almost no transport of 
taurocholate or cholate, while the other variants displayed transport of all three substrates with 
comparable affinities. All the variants were later shown to mediate rosuvastatin transport 
[126]. The p.S267F variant showed a higher transport capacity for rosuvastatin than NCTP*1 
and a much higher affinity (3 μM versus 65 μM) than NTCP*1, despite exhibiting almost no 
detectable bile salt transport. To date, no genotype phenotype correlations (e.g. serum bile salt 
levels) of NTCP variants have been published. Serum bile salt levels, if at all, would certainly 
not only be determined by NTCP variant function, but also by NTCP expression levels, which 
have been reported to be subject to considerable interindividual variability at the mRNA level 
[126]. 
 
In summary, Ntcp/NTCP is the major hepatocyte system for uptake of conjugated bile salts 
from the portal blood. Ntcp transports bile salts into hepatocytes in a sodium-dependent 
manner and works electrogenically against a concentration gradient. Ntcp prefers conjugated 
to nonconjugated bile salts and exhibits a substrate specificity largely restricted to bile salts, 
sulfated steroids, and a limited number of drugs or drug metabolites. Ntcp's expression is 
 13
extensively regulated at the transcriptional and posttranscriptional level in many 
pathophysiologic situations. Ntcp expression is typically down regulated in situations where 
bile secretion is impaired to protect hepatocytes from accumulating cytotoxic bile salts. The 
transcriptional regulation of Ntcp will be covered elsewhere in this book. 
 
3. The bile salt export pump Bsep/BSEP 
 
3.1. Molecular Properties 
 
Bsep was cloned based on the hypothesis that it belongs to the ABC-transporter family [32, 
201]. PCR analysis of total rat liver mRNA with degenerate oligonucleotide primers spanning 
the Walker A and Walker B motif of ABC-transporters identified a c DNA fragment that 
revealed a high identity with a published cDNA fragment isolated from pig liver [94]. This 
partial cDNA had been named sister of p-glycoprotein [47, 94, 296]. Expression of the full-
length cDNA of the rat liver isoform of the sister of p-glycoprotein in X. laevis oocytes 
demonstrated a stimulation of taurocholate efflux and membrane vesicles isolated from Sf9 
cells expressing this cDNA exhibit ATP-dependent bile salt transport [94]. Sister of p-
glycoprotein was therefore renamed bile salt export pump (Bsep). Analysis of the genome of 
patients with progressive familial intrahepatic cholestasis type 2 by positional cloning 
identified the genetic defect to be located in the human ABCB11 or BSEP gene [300]. The 
BSEP gene is located on chromosome 2q24-31, spans 28 exons and encodes 1321 amino acids. 
Mouse and rat Bsep are more than 80 % identical to human BSEP, whereby the difference 
between the species are mostly found in the predicted transmembrane helices, while the 
cytoplasmic loops display very little variability [100, 192, 238]. Mouse Bsep is located to a 
region on chromosome 2, which is syntenic to human 2q24-31 [192]. Bsep has recently been 
cloned and characterized from dog and shown to be highly homologous to human and rat 
Bsep [347]. BSEP is a glycoprotein with four putative N-linked glycosylation sites and with a 
molecular weight of 140 to 170 kDa [34, 94, 100, 217, 240]. Rat Bsep is glycosylated at all 
four putative glycosylation sites [225]. In addition to glycosylation, phosphorylation of Bsep 
[114, 238] and ubiquitination occur as additional posttranslational modifications. 
 
The structure of BSEP has not yet been determined. It is a member the ABCB family of the 
human ABC transporters, which also contains MDR1 or P-glycoprotein [94, 314] and it is 
predicted to have two transmembrane domains of six membrane spanning helices each. The 
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transmembrane domains are separated by a large cytoplasmic domain and the second 
transmembrane domain is again followed by a large cytoplasmic domain [94]. This structural 
organization constitutes the basic building principle of all ABC transporters [25, 120, 159]. 
The cytoplasmic domains harbor the Walker A and Walker B motifs, which are part of the 
ATP-binding site as well as the family signature motif of ABC transporters. Analysis of 
inherited defects in the human BSEP gene has provided a wealth of information on the 
functional role of individual amino acids within the BSEP protein. These findings will be 
discussed in the following section. Recently, a first report of findings on quantitative 
structure-activity relationship analysis using BSEP inhibitors has been published [123]. 
Pursuing this approach will certainly provide most valuable information on the structural 
requirements of substrates and inhibitors for their interaction with Bsep. 
 
3.2. Subcellular expression and tissue distribution 
 
Bsep is expressed homogenously throughout the liver acinus and located in the canalicular 
membrane of hepatocytes as demonstrated by immunohistochemical methods at the light and 
electronmicroscopic level [94]. Using imunogold labeling, Bsep was found to be expressed on 
canalicular microvilli, but absent from intermicrovillar parts of the cananicular membrane 
[94]. Hence, Bsep could partition into subdomains of the canalicular plasma membrane. This 
assumption is supported by the observation that Bsep is concentrated in canalicular 
microdomains, which are resistant to extraction by Lubrol WX [141]. Bsep is also expressed 
in subapical vesicles in close proximity to the canalicular plasma membrane [62, 94]. 
 
In pig, rat and mouse, Northern blot analysis revealed a predominant if not exclusive 
expression of Bsep in liver [47, 94, 192]. Using a PCR approach, Bsep mRNA was found in 
liver, brain, small and large intestine but not kidney of rats [317]. Another group identified 
Bsep both by PCR and by Western blotting in rat kidney [118]. In dog, very low levels of 
Bsep mRNA were demonstrated with PCR in testis, spleen, and stomach, while expression in 
heart, lung, kidney, skeletal muscle, large and small intestine was not detectable [347]. In 
humans, BSEP mRNA was found at high levels in testis in addition to liver by quantitative 
PCR. Low levels were reported for trachea, colon, prostate, lung and thymus [187]. In another 
study, moderate expression was found in kidney and colon, but jejunum was reported negative 
[122]. Low BSEP expression has also been reported for the first trimester human placenta 
[246] and very low levels in rat placenta [289]. Taken together, while there is no doubt that 
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Bsep is expressed at a high level in the liver, data on extrahepatic expression revealed 
conflicting results so far. In particular, with the exception of one study, no information is 
available on the expression BSEP protein in extrahepatic tissues. 
 
3.3. Phylogenetics and ontogenesis 
 
Bsep is also found in lower vertebrates. Bsep of the small skate Raja erinacea, an ancient 
vertebrate, is 69 % identical to human BSEP [35]. Hence BSEP remained remarkably 
conserved during vertebrate evolution. A partial Bsep sequence was also cloned from flounder 
(Pseudopleuronectus americanus) [47] and a highly identical sequence could be amplified 
from rainbow trout (Oncorhynchus mykiss) hepatocytes [350]. Using Northern blot analysis, 
Bsep expression was also identified in liver from the two vertebrates chicken and turtle [94]. 
 
The ontogeny of Bsep has been extensively studied in rat liver. Bsep mRNA could be 
detected at day 15 [85, 315 289, 356] and stayed at very low level until day 20 of gestation. In 
rats, low levels of Bsep staining can be detected at the canaliculi at embryonic day 20. From 
day 20 on, Bsep expression rapidly increases both at the mRNA and at the protein level, 
reaching almost adult levels within the first week after birth [85, 315 356]. One group has 
reported a transient increase of Bsep mRNA above adult levels in rats in the first days after 
birth [59]. In mouse liver, Bsep mRNA is reported at day 14 in developing liver [192]. In 
humans, BSEP is expressed at mid gestation, albeit at much lower levels than in adult liver 
[41]. The fact that Bsep has not yet reached adult levels at birth explains the observation that 
healthy human neonates have a transient elevation of physiologic bile salts in their serum 
[302]. In summary, in rats ontogeny of the major bile salt uptake (Ntcp) and export (Bsep) in 
parallel one another and closely follow the development of the bile salt pool and the 
enterohepatic circulation of bile salts [198, 305]. 
 
3.4. Transport properties 
 
Hepatocellular, ATP-dependent bile salt transport has been first described in isolated rat 
canalicular plasma membrane vesicles [3, 233, 237, 297]. Molecular characterization of a bile 
salt export system is best done in a vesicular system. Isolated membrane vesicles are oriented 
in part inside out and do therefore allow direct experimental access to the cytoplasmic side of 
the transporter. Furthermore, transport in a vesicular system can be measured as uptake. 
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Hence, isolated canalicular vesicles can be considered to resemble the physiologic 
characteristics of the bile salt export system. Characterization of this system demonstrated that 
bile salt transport in the canalicular membrane cannot be stimulated by nucleotides other than 
ATP and requires the hydrolysis of the γ-phosphate ester [3, 233, 237, 297]. The transport is 
sensitive to orthovanadate and is electrogenic. It can be stimulated by the presence of the 
more permeable anion nitrate in the transport buffer as compared to gluconate [297]. Other 
indirect coupling mechanisms for transmembrane taurocholate transport such as an ATP-
dependent pH gradient or an inside positive membrane potential were excluded as driving 
forces in the same study. Cloned rat Bsep expressed in Sf9 cells has comparable transport 
properties to ATP-dependent bile salt transport in isolated rat canalicular plasma membrane 
vesicles and is also strictly dependent on hydrolysable ATP and not stimulated by other 
nucleotides [94, 295]. 
 
A comparison of the functional characteristics of the cloned Bsep isoforms from different 
species with the respective transporter results in canalicular vesicles (table 3) demonstrates 
that Bsep is predominantly, if not exclusively a bile salt transporter. No overt effect of 
different expression systems on the substrate pattern and on the affinity of the substrates is 
observed. With respect to glycocholate transport activity of rat Bsep, the results vary between 
research groups and expression systems, but this bile salt seems to be a poor substrate for rat 
Bsep. While taurolithocholate-3 sulfate is not transported by rat Bsep expressed in Sf9 cells [5, 
94, 293], it is minimally transported after Bsep expression in HEK 293 cells [116]. In contrast, 
taurolithocholate-3 sulfate is a substrate of human BSEP expressed in HEK293 cells [116]. 
Unconjugated bile salts are, if at all, poor substrates for rat Bsep, as demonstrated for isolated 
canalicular plasma membrane vesicles or for Bsep expressed in Sf9 cells [94]. This 
observation was confirmed in MDCK cells simultaneously expressing rat Ntcp and Bsep in a 
polar manner, were transcellular transport of cholate was marginal, while considerable 
transport of chenodeoxycholate and ursodeoxycholate was observed and excellent transport 
for all conjugated bile salts tested [223]. A similar study with human NTCP and BSEP 
expressed in LLC-PK1 cells identified again cholate, chenodeoxycholate and 
ursodeoxycholate as BSEP substrates together with all conjugated bile salts tested [221]. In 
contrast, BSEP expressed in SF9 cell vesicles does not transport cholate [221, 240], which 
parallels the virtual absence of unconjugated bile acids in the bile from patients with a defect 
in bile acid conjugation [37]. Neither the human nor the rat orthologue of Bsep transport 
lithocholate [221, 223]. The fluorescent bile salt derivatives cholylglycylamidofluorescein and 
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chenodeoxycholylglycylamidofluorescein [221], but not cholyl-L-lysyl-fluorescein [58] are 
BSEP substrates. These results indicate that similar to Ntcp, also for Bsep the bile salt side 
chain is an important substrate determinant. Comparison of the side chains of 
cholylglycylamidofluorescein and cholyl-L-lysyl-fluorescein reveals that the fluorescent Bsep 
substrate has one negative charge, while the non-transported bile salt derivative carries two 
negative charges and is transported by mouse and rat Mrp2 [58]. Hence, it is highly 
suggestive that bile salt derivatives with two negative charges are not substrates for Bsep but 
rather for Mrp2 [293] with the above mentioned exception of taurolithocholate-3 sulfate. 
While it becomes clear from table 3 that different expression systems have only a minimal 
effect on Bsep transport activity of conjugated bile salts, it is interesting to note that the 
transport activity positively correlates with the cholesterol content of the system used for 
transport assay [157, 158, 252]. Different cholesterol content of the membrane system has a 
marked effect on the maximum transport velocity, but only a minor effect on the affinity of 
Bsep to bile salts. In rat canalicular membranes, Bsep partitions into Lubrol WX induced 
microdomains, which are enriched in cholesterol [141]. Hence, also in situ in rat liver, 
cholesterol content of the microenvironment of Bsep might modulate its transport activity. 
Whether Bsep activity is absolutely dependent on the presence of cholesterol is unknown at 
the moment, as insect cell membrane vesicles are not absolutely free of cholesterol, but 
contain a very low amount of this lipid (unpublished observation). A comparison of the 
intrinsic clearances of mBsep, rBsep and BSEP showed the same rank order [240], indicating 
that the transport properties of Bsep are well preserved between different species. In general, 
there is a good correlation of the transported substrates between different species with one 
notable exception: taurolithocholate-3-sulfate is not transported by rat Bsep but by human 
BSEP [5, 116, 293]. So far, only pravastatin has been identified as a non bile salt substrate for 
BSEP whereby the human orthologue displays a higher transport capacity than its rat 
counterpart [124]. The different isoforms of Bsep do display bile salt stimulated ATPase 
activity, again supporting a direct coupling of ATP-hydrolysis to substrate transport [34, 157, 
158, 238]. 
 
3.5. Bsep inhibitors 
 
The sequence of BSEP and MDR1 are closely related [34, 57, 94, 238, 296]. MDR1 is a key 
ABC transporter needed to protect individual cells , organs as well as the entire body from 
xenobiotics [81] MDR1 can be considered to be a cellular vacuum cleaner [121]. Therefore, 
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substrates of MDR1 can also interfere with BSEP function. For example, cyclosporine is 
associated with cholestasis in patients [13]. In rats, cyclosporine has been demonstrated to 
inhibit bile flow and ATP-dependent bile salt transport into canalicular vesicles [23]. After 
cloning of rat Bsep, it was possible to directly demonstrate that cyclosporine is an inhibitor of 
Bsep [293]. 
 
Ongoing inhibition of BSEP will lead to reduced canalicular bile salt secretion and 
consequently to liver injury due to persistent cholestasis [250, 292]. Drug induced liver injury 
including cholestasis is a relevant clinical issue leading to many hospital admissions and in 
severe cases can only be treated with liver transplantation [19]. In addition, drug induced liver 
injury is an important factor leading to attrition of drugs during development or to withdrawal 
of drugs from the market [274, 285]. Among drug induced liver injury in medical inpatients, 
about 30 % are cholestatic or mixed [216]. Unfortunately, is not possible estimating from the 
literature to what extent cholestatic liver injury is caused by direct BSEP inhibition [10, 39, 
202]. As inferred from patients with inherited nonfunctional BSEP, serum γ-
glutamyltransferase should not be elevated as a consequence of direct BSEP inhibition by 
drugs [56]. It should however be noted that biliary excretion of toxic drug metabolites may 
lead to cholangiocyte injury and elevation serum γ-glutamyltransferase [145], which 
complicates the picture. Therefore, the demonstration of direct BSEP inhibition by a given 
drug in a patient with drug induced liver injury may be very difficult. Using Sf9 cell vesicles 
expressing Bsep, cyclosporine, rifamycin SV, rifampicin and glibenclamide were shown to be 
competitive inhibitors of rat Bsep. The Ki value of Bsep inhibition was comparable to Ki 
values in rat canalicular plasma membrane vesicles (table 4) [293]. Extending these studies to 
human BSEP expressed in insect cells demonstrated that cyclosporin A, rifampicin and 
glibenclamide also inhibit human BSEP in a competitive manner (table 4). The clinical 
relevance of Bsep inhibition by a drug was worked out in detail with bosentan. Bosentan and 
one of its main metabolites are dual endothelin receptor antagonists. Their main route of 
elimination is via bile and they are taken up by OATP1B1 and OATP1B3 into hepatocytes 
[321]. During clinical trials, bosentan caused asymptomatic, reversible transaminase 
elevations in some patients [72]. This incidence of liver injury was dose dependent and 
plasma bile salt levels increased with increasing dose of bosentan. Individuals, which in 
addition to bosentan were taking glyburide, showed a higher incidence of liver injury than 
patients on bosentan alone. Studies with rat Bsep and human BSEP expressed in insect cell 
vesicles demonstrated that bosentan and one of its metabolites are competitive Bsep inhibitors 
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[72, 240]. Bosentan treatment of rats lead to an elevation of plasma bile salt levels, which was 
more pronounced if glibenclamide was coadministered [72]. Therefore, the fact that the serum 
bile salt levels positively correlated with bosentan dose and the rapid spontaneous 
normalization of serum liver parameters after discontinuing the drug strongly suggests that 
also in vivo bosentan acts as a competitive BSEP inhibitor. This effect may be rather specific 
for BSEP, as no elevation of serum bilirubin was observed in these patients [72]. The list of 
Bsep/BSEP inhibitors is continuously growing (table 4). In general, the data are very coherent 
between studies using isolated canalicular plasma membrane vesicles and heterologously 
expressed Bsep. Also, species differences of the inhibition results are minor. Therefore, in 
vitro screening of the interaction of drugs with BSEP may be a valuable tool during 
development to assess their potential for inducing cholestasis and liver injury. 
 
Estrogens, such as the oral contraceptive ethinylestradiol or estrogen metabolites are known to 
be cholestatic in humans and animals [196, 329]. In animal experiments, the estrogen 
metabolite estradiol-17β-glucuronide has been demonstrated to be strongly cholestatic. The 
cholestatic action of estradiol-17β-glucuronide was found to be dependent on the expression 
of Mrp2 in the canaliculus of rats [137]. Interestingly, when tested as an inhibitor of Bsep in 
Sf9 cell vesicles, estradiol-17β-glucuronide did not inhibit ATP-dependent taurocholate 
transport [293]. However, in canalicular plasma membrane vesicles from normal rats and in 
Sf9 cell vesicles coexpressing Bsep and Mrp2, estradiol-17β-glucuronide inhibited Bsep 
mediated taurocholate transport in a time- and dose-dependent manner [293]. This is in line 
with the observation from rat experiments that Mrp2 is strictly required for the cholestatic 
potential of estradiol-17β-glucuronide. Hence, Bsep can also be indirectly inhibited and it was 
postulated that estradiol-17β-glucuronide inhibits Bsep by trans-inhibition, i.e. it needs to be 
secreted into the canalicular lumen to exert its inhibitory and consequently cholestatic 
property [293]. Indirect Bsep inhibition was later confirmed and extended to sulfated 
progesterone metabolites [5, 322]. The HER1/HER2 inhibitor PKI166 was also described to 
inhibit Bsep indirectly [310], extending the mechanism of indirect Bsep inhibition to drugs. 
Most interestingly, in a follow-up study on the mechanism of bosentan-induced cholestasis in 
rats demonstrated that bosentan leads to a stimulation of bile flow and not – as expected – to a 
reduction of bile flow [79]. While bile flow was increased after administration of bosentan, 
bile salt output remained unchanged leading to a lower bile salt concentration in bile 
concomitant with a reduced biliary lipid secretion. The stimulation of the bile flow was again 
dependent on the presence of functional Mrp2 in the canaliculus. Hence, bosentan presents an 
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additional albeit mechanistically different example of the involvement of Mrp2 in the 
cholestatic effect of substances. In Sf9 cell vesicles expressing rat and human Mrp2/MRP2 or 
Bsep/BSEP the inhibition of taurocholate transport by bosentan was confirmed for both 
isoforms of Bsep/BSEP [206]. Moreover, this study demonstrated that the transport activity of 
Mrp2/MRP2 is directly stimulated by bosentan and hence provides a mechanistic explanation 
the observed increase of bile salt independent bile flow in rats. Taken together, drug induced 
liver injury through inhibition of BSEP is now well established. Bsep can either be inhibited 
directly (competitively) by drugs acting from the cytoplasm or indirectly, most probably from 
the canalicular side. This latter process needs the presence of Mrp2, as the drugs need to be 
secreted into the canaliculus prior to their interaction with BSEP. 
 
3.5. Pathophysiology 
 
Liver disease as a consequence of impaired BSEP function can either be acquired or inherited 
[251]. Acquired forms of liver disease affecting BSEP function include its inhibition by drugs 
and xenobiotics, obstructive or intrahepatic cholestasis, inflammatory liver diseases such as 
sepsis or acute and chronic hepatitis. For the purpose of this review, primary biliary cirrhosis 
and primary sclerosing cholangitis are also considered to be acquired forms of BSEP 
impairment, as in neither of these diseases BSEP alterations seem to be the primary cause. 
 
Several studies have investigated the expression of BSEP in specimens from patients with 
liver disease. After percutaneous transhepatic biliary drainage, mRNA for BSEP was 
significantly down-regulated in patients with poor drainage in comparison to patients, which 
were well drained or to controls. Poorly drained patients had about 6-fold higher serum bile 
salt levels in comparison to the well drained patients [279]. Immunostaining of BSEP 
displayed the canalicular membrane, but was presenting with a fuzzy staining extending into 
the subcanalicular area. This fuzziness was very pronounced in poorly drained patients. 
Pediatric patients with biliary atresia show down regulation of BSEP mRNA at early stages 
and no mRNA change at late stages. The signal intensity and canalicular immunofluorescence 
staining of BSEP is comparable in all stages to control livers [42]. BSEP expression is also 
down-regulated in patients with inflammatory cholestasis, but not with primary biliary 
cirrhosis stages I and II or primary sclerosing cholangitis [161, 357, 358], while another group 
reported upregulation of BSEP in primary biliary cirrhosis [263]. Immunostaing of BSEP was 
conserved as well. Down regulation of BSEP in inflammatory liver disease is also observed at 
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mRNA and protein level after incubation of human liver slices with LPS [68] and in human 
hepatocytes after treatment with IL-1β [188]. In a small cohort of patients with cholesterol 
calculus, BSEP expression was reduced at the mRNA and protein level in comparison to 
control livers [162]. Ursodeoxycholate is used to treat cholestatic liver disease [18]. In a study 
with healthy gallstone patients, treatment with ursodeoxycholate, but not with rifampicin 
leads to an upregulation of BSEP at the protein level, while mRNA level remained unchanged 
[212]. In patients who underwent liver transplantation, bile salt secretion is increased early 
after transplantation, which is paralleled by increased BSEP mRNA levels in these livers [95]. 
Alterations of BSEP expression in hepatocellular carcinomas seems to be highly variably and 
not display a consistent pattern, but may tend to be reduced [324, 359]. 
 
In rat models of obstructive cholestasis and of ethinylestradiol induced cholestasis, Bsep is 
modestly down-regulated [193] or practically unchanged [63]. However, functional analysis 
of canalicular vesicles isolated from the liver of rats treated with ethinyl-estradiol showed a 
marked reduction of ATP-dependent taurocholate transport activity, suggesting a role of 
posttranslational processes in this model of cholestasis [26]. Supporting this assumption, 
relocation of Bsep into subapical vesicles has been observed in rats with estradiol-17β-
glucuronide induced cholestasis [53]. Internalization of Bsep was also observed in rats treated 
with lithocholate and taurolithocholate, which can be prevented by preadministration of 
cAMP [52, 54] or of tauroursodeoxycholate [62]. A modest down-regulation of Bsep is also 
observed in primary cultured rat hepatocytes, which display a cholestatic expression pattern of 
organic anion transporters [261]. Treatment of rats with LPS has also been reported to alter 
the canalicular localization of Bsep in rats [330, 355]. In mice, Bsep tends to be upregulated 
after bile duct ligation [283]. The sepsis model of treating rats with LPS leads to a mild down 
regulation of Bsep at the mRNA and at the protein level [63, 193, 330] and a more fuzzy 
expression of Bsep in the canalicular membrane, while the down-regulation is more 
pronounced in mice [110]. Treating rats with CCl4 is a model for toxic liver injury has no 
effect on the expression of Bsep [91]. Cold ischemic injury prior to transplantation of mouse 
livers modelling bile duct injury leads to a down regulation of Bsep. Hypoxia induces a down 
regulation of Bsep in rat and mouse liver [78, 128]. Fatty liver disease in obsese Zucker rats is 
paralleled by a slight down regulation of Bsep [255], while in fatty livers of chronically 
ethanol fed rats, Bsep is upregulated at the mRNA and protein level [354]. Taken together, in 
animal models of liver injury, Bsep is only mildly affected at the expression level but may 
alter its subcellular localization [92, 262]. This maintenance of Bsep, together with the 
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upregulation of basolateral salvage systems, may be a cytoprotective effect as it will help to 
keep intracellular cytotoxic bile salt concentrations at a low level. 
 
During pregnancy, Bsep is not upregulated in the liver of the mother, but it increases 
postpartum [36]. Functionally, prolactin treatment of ovarectomized rats leads to an increase 
of ATP-dependent bile salt transport into canalicular vesicles without a change of the Km 
value [199]. After partial hepatectomy as a model for the regenerating liver, Bsep expression 
remains practically unchanged at the mRNA and at the protein level [331] or is mildly 
upregulated [64, 93]. This is paralleled by an unchanged ATP-dependent taurocholate 
transport into isolated canalicular plasma membrane vesicles from regenerating rat liver [99]. 
 
Bile flow and in particular canalicular bile salt secretion is a highly regulated process. As 
Bsep is the rate limiting step of hepatocellular bile salt transport [260], it is also regulated by 
various posttranslational mechanisms. In isolated perfused rat livers, stimulation of biliary 
bile salt secretion by dibutyrylcAMP is paralleled by a stimulation of transcytotic vesicular 
transport processes [112]. This together with the observation that cholestasis can lead to a 
retrieval of Bsep into subapical vesicles, is strongly suggestive for a regulation of Bsep via 
endo- and exocytosis. This stimulation of bile salt secretion is independent of Bsep 
biosynthesis, but sensitive to the microtubule disrupting agent colchicine [11, 88]. Treatment 
of rats with taurocholate or dibutyl cAMP leads to a rapid insertion of Bsep into the 
canalicular membrane [88, 333]. As this process is sensitive to colchicine, Bsep is inserted 
from a preexisting intracellular pool. cAMP-mediated stimulation of Bsep insertion can be 
inhibited by inhibition of PI3 kinase [11, 220]. Different from other canalicular ABC 
transporters such as for example p-glycoprotein, Bsep needs about 2 hrs from the endoplasmic 
reticulum to the canalicular plasma membrane (as opposed to about 30 min. for others) [155, 
156, 262]. Based on the kinetic analysis of the biosynthesis and on the short-term 
incorporation of Bsep from an intracellular reservoir, two different intracellular vesicular 
pools for Bsep were postulated [155, 333]. The trafficking from the Golgi to the apical 
membrane in HepG2 cells requires the activity of MAP kinase p38 [173]. In the model 
hepatocyte cell line WifB, Bsep constitutively recycles between the canalicular membrane 
and a rab11 positive endosomal compartment [334]. As an additional regulatory element, 
Ca2+-dependent protein kinase C isoforms also modulate canalicular insertion/retrieval of 
Bsep [11, 18, 62, 172, 262]. This complex intracellular trafficking of Bsep not only requires 
correct glycosylation [225], but also proteins directly binding Bsep. Experiments in a 
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polarized cell line revealed that Bsep needs myosin II regulatory light chain and HAX-1 for 
proper targeting to the apical membrane as well as for the regulation of Bsep density in the 
apical membrane of MDCK cells [40, 242]. In the Sf9 cell system, protein kinase Cα mediates 
phosphorlyation of mouse Bsep [238]. It is hence conceivable that the activity of Bsep is also 
under the control of posttranslational modifications occurring within the cananliclar plasma 
membrane [11]. While posttranslational regulation is usually a short term process, adaptation 
to pathophysiologic situations needs much more time. The half life of Bsep in rats is 4 to 6 
days [156]. To what extent ubiquitination regulates the half life of Bsep is not known in detail 
at this moment [114]. In summary, the strategic position of Bsep in the enterohepatic 
circulation of bile salts is governed by complex adaptive and regulatory mechanisms of Bsep 
function in health and disease [11, 155, 262]. Many studies have elucidated the factors and 
mechanisms governing transcriptional regulation of BSEP/Bsep. This topic is the focus of 
another chapter in this issue. 
 
3.7. Mutations in the BSEP Gene 
 
The key role of BSEP in hepatocellular bile salt secretion is highlighted in patients with 
mutations in the BSEP [56, 244]. Such patients have less than 1 % than normal of primary bile 
salts in their bile concomitant with absent Bsep expression [142]. They develop severe liver 
disease with progressive familial intrahepatic cholestasis type 2 (PFIC2) [56, 244, 300]. This 
demonstrates that there exists no backup system for BSEP in the canalicular membrane. Many 
such patients are now described in the literature [6, 56, 301]. A milder variant of this disease 
often comes with recurring episodes of cholestasis and is called benign recurrent intrahepatic 
cholestasis. A group of such patients also present with mutations in the BSEP gene [326]. 
Taken together, mutations in the BSEP gene represent a continuum from mild to severe forms 
of intrahepatic cholestasis, which are often progressive [181, 251, 311]. They lead to BSEP 
deficiency syndrome [181, 251]. The frequently occurring mutations in the BSEP gene can be 
grouped into missense mutations, nonsense mutations, deletions, insertions and splice site 
mutations. A recent exhaustive study analyzed 109 families of patients with severe BSEP 
deficiency syndrome and identified 82 different mutations [301]. Mutations identified in these 
patients cluster in the two nucleotide binding domains of BSEP. This is in line with the high 
conservation of this domain between different species [238] and highlights the importance of 
a correct structure of the two nucleotide binding domains for proper functioning of ABC-
transporters [200, 259, 276]. The former study also investigated BSEP expression by 
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immunohistochemistry in the available biopsies and found that the vast majority of patients 
had abnormal or absent BSEP staining, whereby lack of Bsep staining was clearly dominating 
[301]. The number of known mutations continues to rise [43, 320]. Hence, mutations in the 
BSEP gene lead often to absent BSEP expression, which may be due to quality control of 
protein synthesis in the endoplasmic reticulum. Experimental support for this hypothesis is 
currently missing, as no large studies on mRNA levels in patients with BSEP deficiency 
syndrome are published so far. Another interesting finding of this study [301] is the 
observation that the two common E297G and D482G mutants of BSEP varied most in their 
expression level among the respective carriers. This is notable, as E297G and D482G variants 
have been demonstrated to display residual [239] or normal [115] transport activity, 
respectively. In an important continuation of the genetic and histological characterization of 
patients with bile salt deficiency syndrome, the consequence of mutations and single-
nucleotide polymorphisms in the BSEP gene on the fidelity of pre-mRNA splicing and of the 
subsequent processing of BSEP protein was investigated [33]. In this study, 20 
mutations/SNPs were identified, which resulted in reduced splicing activity compared to the 
wild-type BSEP gene and consequently reduced levels of normal mRNA in vitro. Furthermore, 
aberrant splicing and exon skipping was reported for BSEP mutations. The majority of the 
mutants, after expression in CHO-K1 cells, led to protein retention in the endoplasmic 
reticulum and subsequent degradation. This explains the lack of staining of BSEP expression 
in liver biopsies of such patients. Importantly and interestingly, the common European mutant 
D482G shows an enhanced aberrant splicing. This finding could provide a possible 
explanation for the wide variation of BSEP expression observed in patients with D482G 
mutations with consequently leading to clinical phenotypes with variable severity. Recently, 
patients who developed antibodies against BSEP were reported [143, 147]. These patients 
also developed persistent or transient severe progressive cholestasis. While the patient died, 
the others could be rescued by a more aggressive immunosuppressive regimen. This 
constitutes a novel form of acquired (or primary) BSEP deficiency syndrome, as it was not 
anymore possible to determine the onset of the (auto)immune reaction. 
 
Missing or non-functional BSEP leads to accumulation of bile salts within hepatocytes of the 
affected patients. Patients with severe forms of BSEP deficiency syndrome, who are often 
very young, are at significant risk to develop hepatocellular carcinoma very early in life [160, 
301]. The exact mechanism how chronically elevated intracellular bile salts are transforming 
hepatocytes into cancer cells is not yet known to detail. It is considered likely that bile salt 
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induced carcinogenesis involves mitochondrial damage, since bile salts are toxic to 
mitochondria [245, 287]. Alternate or additional mechanisms of cell transformation may 
include interference of bile salts with signaling cascades controlling the cell cycle [15] or 
activation of homeobox genes [288], or interference with DNA repair mechanisms. And 
finally, bile salts have been demonstrate to reversibly induce differentiation and cell 
polarization of rat hepatoma cells, again highlighting pleiotropic action of intracellular bile 
salts [235]. 
 
3.8. Pharmacogenomics of BSEP 
 
Inborn errors of bile salt biosynthesis lead to the formation of aberrant bile salts [308]. These 
metabolites inhibit ATP-dependent bile salt transport and hence lead to cholestais [298, 308]. 
Some patients with cholestasis of pregnancy were found to have a novel mutation in the BSEP 
gene, leading to a p.N591S variant [61, 248]. These two groups of patients have an acquired 
form of BSEP deficiency syndrome. Such inherited forms of acquired cholestasis are rare. In 
contrast, inhibition of BSEP by drugs (table 4), is more frequent and leads to acquired BSEP 
deficiency syndrome and intrahepatic cholestasis. Drug induced cholestasis is a clinically 
important and often severe problem [249]. However, the risk for such events is very low (e.g. 
8.5 per 100,000 in the first 45 days for first time users of flucloxacillin [265]). It is therefore 
evident that patients suffering from adverse drug reactions leading to acquired intrahepatic 
cholestasis could carry genetic susceptibility factors. To date, c.1331T>C (p.V444A) in exon 
13 and c.2029A>G (p.M677V) in exon 17 of the BSEP gene are two nonsynomous SNPs, 
which consistently have been found with frequencies higher than 0.5 % [186, 247, 268, 291, 
296] in different, unrelated cohorts. Interestingly, the p.444A variant is found with a 
considerably higher frequency in the Japanese population than in Caucasians [154, 186]. A 
comparative study of protein expression levels of four canalicular ABC transporters 
demonstrated a considerable interindividual variability of protein expression for all the 
investigated transporters (BSEP, MDR1, MDR3, MRP2) [217]. Strikingly, individuals 
carrying the p.444A variant are associated with a lower than mean BSEP expression level and 
all of the 17 % of the 110 individuals having low or very low BSEP expression levels were 
carrying at least one c.1331T>C allele. Kinetic characterization of these two BSEP variants 
expressed in Sf9 cells revealed no difference in their transport properties [185]. From this 
finding, it can be postulated that individuals carrying the p.444A variant might be at a higher 
risk for developing acquired BSEP deficiency syndromes. This hypothesis is supported by 
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findings in independent patient cohorts with drug induced cholestasis [185] and in patients 
with intrahepatic cholestasis of pregnancy [61, 218], whereby in all studies the c.1331T>C 
variant of BSEP was significantly more frequent than in controls. These three studies 
therefore identified the c.1331T>C variant of BSEP as a susceptibility factor for acquired 
BSEP deficiency syndrome. Using CHO-K1 cells as a heterologous expression system, the 
p.444A variant was observed to lead to a lower BSEP protein expression than the p.444V 
variant [33], thus corroborating the finding in human liver [217]. It should however be 
mentioned that a study of a Swedish cohort with intrahepatic cholestasis of pregnancy did not 
find a difference in the distribution of common BSEP haplotypes compared to controls [342]. 
This discrepancy could in part relate to the fact that this study investigated haplotypes, while 
the above studies investigated frequencies of SNPs. In further support of this hypothesis, five 
case reports (3 patients with cholestasis of pregnancy and one patient with benign recurrent 
intrahepatic cholestasis type 2 and in one patient with a heterozygous mutation in the 
ATP8B1 gene), observed homozygocity for p.444A three times and heterozygocity for 
p.444A twice [73, 136, 150, 171, 229]. Clearly, while the association of a common BSEP 
variant with increased risk for acquired BSEP deficiency syndromes seems now well 
established, independent studies with large cohorts are needed to firmly establish the 
p.V444A polymorphism as risk factor. In addition, given the frequency of this variant in the 
population, additional risk factors, such as for example DNA methylation as an epigenetic 
factors are most likely involved too [139]. So far, one haplotyp of the BSEP promoter was 
reported to lead to a lower transactivation of the BSEP gene in vitro [186]. The clinical 
relevance of this variant has not been reported so far. 
 
Two mutant forms of BSEP, which were identified in a patient heterozygous for the two 
mutants and who presented with benign recurrent BSEP deficiency syndrome exhibited 
residual transport activity when expressed in Sf9 cells [239]. This raises the important 
question as to what minimal level of functional BSEP is required to maintain canalicular bile 
salt secretion and prevent liver injury. It also indicates that in some patients additional 
endogenous or exogenous factors contribute to cholestatic episodes. Since BSEP constitutes 
the rate limiting step of hepatocellular bile salt secretion, it is indirectly also controlling 
systemic bile salt concentrations, as reduced BSEP function will lead to a spill-over of bile 
salts into the systemic circulation. In a large cohort analyzed for single nucleotide 
polymorphisms segregating with the control of fasting glucose levels, an SNP located in the 
vicinity of the BSEP gene was found to positively correlate with fasting glucose levels [45]. 
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In the same cohort, two additional SNPs were identified in intron 19 of the BSEP gene. They 
also strongly associate with fasting glucose levels. Additionally, serum bile salts control 
directly or indirectly via bile salt sensors such as TGR5 or transcription factors having bile 
salts as ligands body energy homeostasis [135, 149, 312, 313, 341]. The modulation of the 
activity of BSEP may therefore have far reaching systemic effects on energy and glucose 
homeostasis. 
 
In summary, the evidence from patients with inherited severe liver disease is now 
overwhelming that BSEP constitutes the most important if not only transporter capable in 
mediating canalicular bile salt secretion. 
 
3.9. In vitro characterization of BSEP variants and animal models for altered Bsep 
expression 
 
There is no doubt that a lot has been learned from patients on BSEP function and on important 
structural/functional elements of BSEP. However, direct mechanistic information on the 
influence of changes in the BSEP protein on its biosynthesis, targeting and stability in human 
liver cannot be gained from this source. Nevertheless, information on these aspects can be 
obtained from heterologous expression systems, which can reproduce "in vivo" phenotypes as 
in "in-vitro phenotypes". Originally, seven BSEP mutations leading to severe BSEP 
deficiency syndrome were characterized by this approach. All investigated mutations were 
situated at highly conserved amino acids in BSEP. These human mutations were introduced 
into the corresponding conserved positions of rat Bsep and the variant Bsep forms 
subsequently expressed in MDCK cells [337]. Five of the studied mutations resulted in 
problems targeting the Bsep protein correctly to the apical membrane and/or showed reduced 
transport activity. Interestingly, the D482G mutation reduced transport activity for human 
BSEP, but had no apparent effect on transport when introduced into mouse Bsep [256]. This 
discrepancy could be due to species differences in the BSEP/Bsep sequence or to differences 
between expression systems. An alternate explanation is that the divergence of results could 
be explained by differences in RNA stability of this BSEP mutant [33]. These variable 
findings argue that multiple expression systems (cells, and/or different species of BSEP/Bsep 
as templates for introducing of mutation) should be used before firm conclusions can be 
drawn regarding the mechanism underlying pathophysiology in the human disease. Different 
in vitro phenotyping studies (table 5) from several groups using different BSEP mutants 
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demonstrated alterations in BSEP targeting [115, 256], a shortening of the half life of BSEP in 
the plasma membrane [115] and differences in ubiquitin dependent BSEP turnover [114]. It 
was recently observed that the severity of BSEP deficiency syndrome phenotype in humans 
correlates with membrane expression and protein stability of the BSEP mutants in 
heterologous expression systems [144, 182]. Of note, it was recently demonstrated that levels 
of the E297G and the D482G mutants of BSEP could be increased at the apical membrane of 
MDCK cells, if the cells were treated with 4-phenylbutyrate [113] or with short and medium-
chain fatty acids [146]. This suggests a possibility for a pharmacologic treatment of some 
forms of inherited BSEP deficiency syndrome. 
 
An alternate approach to better understand the molecular pathophysiology of missing Bsep is 
the use of genetically modified mice. Mice with a disrupted Bsep gene do not develop severe 
cholestasis on a normal diet [340] but only after being fed with a high cholate diet [339]. In 
mice lacking Bsep, novel tetrahydroxylated and hence more hydrophilic bile salts have been 
detected in their bile [254, 340]. An extended screen of gene expression in these knockout 
animals found an upregulation of p-glyocoprotein [339]. As a consequence of this finding, p-
glyoprotein was further investigated and found to be able of mediating bile salt transport 
[183]. Generating mice lacking both Bsep and p-glycoprotein indeed confirm this hypothesis 
[183, 338]. Such mice have a much more severe phenotype with jaundice, a more pronounced 
reduction of bile flow and an increased mortality. Very interestingly, these animals do 
nevertheless not have increased serum bile salt levels but their bile salt levels tend to be lower 
than in wild type animals. As alkaline phosphatase is highly elevated in the serum, these mice 
seem to have high a bile salt concentration in their hepatocytes. Instead of knocking out 
functional Bsep, it can be over-expressed in the liver. Such mice display an enhanced biliary 
lipid (phospholipid and cholesterol) secretion in parallel to their increased bile salt output [75]. 
This supports the concept that canalicilar bile salt and lipid secretion are tightly linked [284]. 
Furthermore, this over-expression of Bsep markedly reduces steatosis in animals fed with a 
lithogenic diet [75]. Feeding such mice with a lithogenic diet leads to formation cholesterol 
crystals and gallstones [75, 119] confirming a role of Bsep in mice in cholesterol gallstone 
formation. Bsep has previously identified in the Lith1 locus [27]. 
 
4. Conclusion 
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Ntcp and Bsep are the two most important bile salt transporters in liver and both are 
strategically located in the enterohepatic circulation of bile salts. This is also reflected in 
results from the analysis of the hepatic proteome, which shows that hepatocellular bile salt 
transporters are highly abundant in hepatocytes at the protein level [2]. Consequently, both 
transporters are extensively regulated in health and disease. The regulation of these 
transporters is important for coping with changes in hepatic bile salt load, e.g. after a meal or 
in pathophysiologic situations. The general principle of the regulatory mechanisms is to keep 
bile salt concentrations within hepatocytes low to minimize their cytotoxic potential. 
Therefore, uptake, efflux and salvage transporters for bile salts are interconnected at the 
regulatory and functional level. Bsep constitutes the rate limiting step in hepatcellular bile salt 
transport and could also be called the guardian of hepatocellular bile salt concentrations. Thus, 
inherited or acquired forms of liver diseases, which impair the proper functioning of Bsep 
lead to an accumulation of bile salts within hepatocytes and consequently to hepatocellular 
damage or even cell death. While our understanding of substrate specificity as well as 
inhibitory mechanisms of bile salt transporters is advanced, structural information on these 
transporters is still missing. Unfortunately, high resolution structural information, in particular 
on ABC transporters, is difficult to obtain and has remained elusive up to now [200, 259, 276, 
351]. Furthermore, much more information is needed about factors (genetic and acquired), 
which make individuals susceptible to adverse drug reactions in the liver in the context of bile 
salt transport. This will require large genome wide association studies, such as for example 
already performed for common diseases [1] or for specific adverse effects of a statin [197]. In 
addition, more information is needed on regulatory genetic mechanisms such as epigenetics as 
well as on biochemical and cell biological processes underlying drug induced liver injury. 
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Table 1: 
 
Km values of hepatocellular sodium-dependent taurocholate transport determined in different 
experimental systems 
 
Experimental system Km (in μM) Reference 
Rat Ntcp   
Perfused liver 25  [260] 
 61 [60] 
   
Hepatocyte monolayer 33 [325] 
 30 [195] 
 17 [168] 
   
Hepatocyte supsension 19 [275] 
 26 [12] 
 21 [21] 
 12 [175] 
 30 [77] 
 24 [270] 
 44 [266] 
   
Isolated membrane vesicles 56 [140] 
 52 [65] 
 46 [353] 
   
X. laevis oocytes 25 [107] 
   
COS-7 (transient) 29 [30] 
HPTC (stable) 25 [257] 
McArdle RH-7777 (stable) 13 [316] 
COS-7 (transient) 18 [168] 
CHO 9-6 (stable) 34 [273] 
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HepG2 (EGFP-tagged) 25 [178] 
COS-7 (transient) 30 [306] 
HeLa (stable) 8 [111] 
HepG (stable  [101] 
MDCK 14 [223] 
   
Human NTCP   
Hepatocyte suspension 46 [16] 
 62 [271] 
 5 [277] 
 84 [223] 
   
Isolated membrane vesicles 34 [241] 
   
X. laevis oocytes 6 [105] 
   
WIF-B (hybrid between rat hepatoma and human fibroblasts) 6 [163] 
COS-1 (transient) 10 [49] 
Hela (transient) 8 [153] 
CHO (stable) 16 [58] 
Not specified 25 [223] 
   
Mouse Ntcp   
X. laevis oocytes 86 (Ntcp1) [38] 
 14 (Ntcp2) [38] 
   
COS-7 (transient) 18 (Ntcp1) [267] 
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Table 2: 
 
Substrates of Ntcp identified in different expression systems 
 
Experimental system Km (in μM) Reference 
Rat Ntcp   
Bile salts   
Cholate (X. laevis)  [273] 
Cholate (COS-7 transient)  [168] 
Cholate (MDCK)  [223] 
Chenodeoxycholate (MDCK)  [223] 
Ursodeoxycholate (MDCK)  [223] 
Glycocholate (X. laevis)  [273] 
Glycocholate (CHO) 27 [273] 
Glycocholate (COS-7 transient)  [168] 
Glycocholate (CHO)  [31] 
Glycocholate (HeLa)  [111] 
Glycocholate (MDCK)  [223] 
Glycochenodeoxycholate (MDCK)  [223] 
Glycoursodeoxycholate (MDCK)  [223] 
Tauromurocholate (HeLa)  [111] 
Taurohyodeoxycholate (HeLa) 7 [111] 
Taurolagodeoxycholate (HeLa)  [111] 
Taurodeoxycholate (HeLa) 7 [111] 
Tauro-allo-cholate (CHO)  [219] 
Taurocheondeoxchycholate (X. laevis)  [273] 
Taurochenodeoxycholate (CHO) 5 [273] 
Taurochenodeoxycholate (MDCK)  [223] 
Tauroursodeoxycholate (X. laevis)  [273] 
Tauroursodeoxycholate (CHO) 14 [273] 
Tauroursodeoxycholate (MDCK)  [223] 
   
Bile salt and steroid metabolites   
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Estrone-3-sulfate (X. laevis)  [273] 
Estrone-3-sulfate (CHO) 27 [273] 
Dehydroepiandosterone sulfate (HepG2, EGFP-tagged)  [178] 
   
Others   
Sulfobromophthalein (X. laevis)  [214] 
Thyroxine (T4) (X. laevis)  [80] 
3,3’,5-triiodothyronine (T3) (X. laevis)  [80] 
3,3’,5’-triiodothyronine (rT3) (X. laevis)  [80] 
3,3’-diiodothyronine (T2) (X. laevis)  [80] 
Thyroxine sulfate (X. laevis)  [80] 
3,3’,5-triiodothyronine sulfate(X. laevis)  [80] 
3,3’,5’-triiodothyronine sulfate (X. laevis)  [80] 
3,3’-diiodothyronine sulfate (X. laevis)  [80] 
Thyroxine sulfamate (X. laevis)  [80] 
3,3’,5-triiodothyronine sulfamate(X. laevis)  [80] 
ONO-1301 (not specified)  [309] 
Bamet-R2 (CHO) *) [31] 
Bamet-UD2 (CHO) *) [31] 
Sulfobromophthalein (HeLa) 4 [111] 
α-amanitin (Hep-G2)  [101] 
   
Human NTCP   
Bile salts   
Cholate (LLC-PK1)  [222] 
Chenodeoxycholate (LLC-PK1)  [222] 
Chenodeoxycholate-3-sulfate (COS-1 transient)  [49] 
Ursodeoxycholate (LLC-PK1)  [222] 
Glycocholate (LLC-PK1)  [222] 
Glycochenodeoxycholate (LLC-PK1)  [222] 
Glycoursodeoxycholate (HEK293) 0.4 and 25 [205] 
Glycoursodeoxycholate (LLC-PK1) 15 [222] 
Tauroursodeoxycholate (HEK293) 10 [205] 
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Taurochenodeoxycholate (LLC-PK1)  [222] 
   
Bile salt and steroid metabolites   
Estrone-3-sulfate (COS-1 transient) 60 [49] 
   
Others   
Chlorambucil-taurocholate (X. laevis) 11 [177] 
Bromosulfophthalein (X. laevis)  [214] 
Bamet-R2 (X. laevis) 27 [31] 
Bamet-UD2 Bamet-UD2 (X. laevis) 33 [31] 
Rosuvastatin NTCP*1 (HeLa transient) 65 [126] 
Rosuvastatin NTCP*2 (HeLa transient) 3 [126] 
3,3’,5-triiodothyronine sulfate (COS1)  [327] 
Thyroxine sulfate (COS1)  [327] 
 
The heterologus expression system is given in parenthesis. 
*) transport mediated by Ntcp was partially sodium-independent 
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Table 3: 
 
Substrates of Bsep in identified in different expression systems 
 
Experimental system Km (in μM) Reference 
Rat canalicular plasma 
membrane vesicles 
  
Substrate   
Taurocholate 26 [237] 
Taurocholate 8 [233] 
Taurocholate 47 [3] 
Taurocholate 2 [297] 
Taurocholate 6 [199] 
Taurocholate 13 [236] 
Taurocholate 2 [83] 
Glycocholate low [94] 
Cholate low [94] 
   
   
Rat Bsep   
Bile salts:   
Taurocholate (Sf9) 5 [94] 
Taurocholate (Sf9) 8 [5] 
Taurocholate (HEK293) 10 [116] 
Taurocholate (Sf9) 22 [347] 
Taurocholate (Sf9) 12 [157] 
Glycocholate (Sf9) nt [94] 
Glycocholate (HEK293) 10 [116] 
Glycocholate (Sf9) 22 [157] 
Tauroursodeoxycholate 4 [293] 
Taurochenodeoxycholate (SF9) 2 [293] 
Taurochenodeoxycholate 
(HEK293) 
10 [116] 
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Taurochenodeoxycholate (Sf9) 12 [157] 
Glycochenodeoxycholate 
(HEK293) 
6 [116] 
Glycochenodeoxycholate (Sf9) 16 [157] 
Cholate (Sf9) nt [94] 
   
   
Bile salt and steroid metabolites   
Taurolithocholate-3-sulfate 
(Sf9) 
nt [293] 
Taurolithocholate-3-sulfate 
(Sf9) 
nt [5] 
Taurolithocholate-3-sulfate 
(HEK293) 
low [116] 
   
Others:   
Pravastatin (HEK293) yes [124] 
   
Human canalicular plasma 
membrane vesicles 
  
Taurocholate 5 [346] 
Taurocholate 21 [236] 
   
Human BSEP   
Bile Salts   
Taurocholate (Sf9) 8 [240] 
Taurocholate (high five) 4 [34] 
Taurocholate (HEK293) 6 [116] 
Taurocholate (Sf9) 20  [347] 
Taurocholate (Sf9) 15 [157] 
Taurocholate (Sf9) 20 [348] 
Glycocholate (HEK293) 22 [116] 
Glycocholate (Sf9) 11 [240] 
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Glycocholate (Sf9) 36 [157] 
Tauroursodeoxycholate (Sf9) 12 [240] 
Taurochenodeoxycholate (Sf9) 5 [240] 
Taurochenodeoxycholate 
(HEK293) 
7 [116] 
Taurochenodeoxycholate (Sf9) 4 [157] 
Taurochenodeoxycholate 13 [348] 
Glycochenodeoxycholate 
(HEK293) 
8 [116] 
Glycochenodeoxycholate (Sf9) 2 [157] 
Taurodeoxycholate 34 [348] 
Taurolithocholate 4 [348] 
   
Bile salt and steroid metabolites   
Taurolithocholate-3-sulfate 
(HEK293) 
10 [116] 
   
Others:   
Pravastatin (HEK293) 124 [124] 
   
Mouse total plasma 
membrane vesicles 
  
Taurocholate 10 [252] *) 
   
   
Mouse Bsep   
Taurocholate (Balb-3T3) 11 [100] 
Taurocholate, His-tagged (Sf9) 30 [238] 
Taurocholate His-tagged(Sf9) 7 [157] 
Glycocholate, His-tagged (Sf9) 20 [238] 
Glycocholate His-tagge(Sf9) 9 [157] 
Taurochenodeoxycholate, His-
tagged (Sf9) 
6 [238] 
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Taurochenodeoxycholate, His-
tagged (Sf9) 
9 [158] 
Taurochenodeoxycholate, His-
tagged (Sf9) 
17 [157] 
Glycochenodeoxycholate, His-
tagged (Sf9) 
2 [157] 
   
Dog Bsep   
Taurocholate (Sf9) 34 [347] 
   
Skate Bsep   
Taurocholate (Sf9) 15 [35] 
 
The heterologous expression system is given in parenthesis. 
nt: not transported 
*) C.C. Paulusma, personal communication 
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Table 4: 
 
Inhibitors of Bsep identified in different expression systems. 
 
Inhibitor Assay system potency (μM) Reference 
bosentan 
 
 
 
bosentan M2 
rat Bsep (Sf9) 
rat Bsep (Sf9) 
BSEP (Sf9) 
BSEP (Sf9) 
rat Bsep (Sf9) 
Ki 12  
IC50 101 
Ki 37 
IC50 77 
Ki 9 
[72] 
[206] 
[240] 
[206] 
[72] 
bosentan 
 
primary human hepatocytes in 
sandwich culture 
primary rat hepatocytes in 
sandwich culture 
concentration dependent 
 
concentration dependent 
[167] 
 
[151] 
bromosulfophthalein rat canalicular vesicles na [237, 297] 
clofazimine BSEP (Sf9) IC50 2 [157] 
chlorpromazine rat canalicular vesicles Ki 506 [134] 
cloxacillin rat canalicular vesicles 
human canalicular vesicles 
Ki 75 
na 
[134] 
[134] 
colchicine rat canalicular vesicles Ki 539 [134] 
CI-1034 primary human hepatocytes in 
sandwich culture 
concentration dependent [167] 
CP-724,714 BSEP (Sf9) IC50 16 [74] 
cyclosporine rat canalicular vesicles 
 
 
human canalicular vesicles 
Ki 0.2 
Ki 1.1 
IC50 0.8 
Na 
[23] 
[134] 
[83] 
[134] 
cyclosporine rat Bsep (Sf9) 
rat Bsep (Sf9) 
BSEP (high five) 
BSEP (Sf9) 
mouse Bsep (Sf9) 
dog Bsep 
Ki 0.3 
IC50 0.9 
Ki 10 
IC50 19 
IC50 2 
na 
[293] 
[157] 
[34] 
[157] 
[157] 
[347] 
cyclosporine primary human hepatocytes in concentration dependent [167] 
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sandwich culture 
cyclosporine BSEP (LLC-PK1) concentration dependent [221] 
ciglitazone rat canalicular vesicles concentration dependent [286] 
efavirenz BSEP (Sf9) na [213] 
efavirenz primary human hepatocytes in 
sandwich culture 
primary rat hepatocytes in 
sandwich culture 
concentration independent 
 
concentration independent 
[213] 
 
[213] 
Ethinly-estradiol BSEP (Sf9) IC50 16 [157] 
DIDS rat canalicular vesicles na [237] 
doxycycline rat canalicular vesicles Ki 530 [134] 
erythromycin 
estolate 
primary human hepatocytes in 
sandwich culture 
concentration dependent [167] 
fendiline BSEP (Sf9) na [123] 
fluvastatin BSEP (Sf9) IC50 50 [185] 
fusidate rat canalicular vesicles Ki 2 [22] 
GSBSP rat canalicular vesicles na [237] 
glibenclamide rat canalicular vesicles 
 
 
human canalicular vesicles 
Ki 6 
Ki 5 
IC50 9 
na 
[293] 
[134] 
[83] 
[134] 
glibenclamide rat Bsep (Sf9) 
rat Bsep (Sf9) 
BSEP (high five) 
BSEP (SSf9) 
mouse Bsep (Sf9) 
dog Bsep (Sf9) 
Ki 6 
IC50 26 
Ki 28 
IC50 15 
IC50 150 
na 
[293] 
[157] 
[34] 
[157] 
[157] 
[347] 
glibenclamide primary human hepatocytes in 
sandwich culture 
concentration dependent [167] 
glibenclamide BSEP (LLC-PK1) na [221] 
lovastatin not specified na [82] 
mideamycin rat canalicular vesicles 
human canalicular vesicles 
Ki 154 
na 
[134] 
[134] 
nefazodone primary human hepatocytes in IC50 14 [166] 
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sandwich culture 
nefadozone BSEP (Sf9) IC50 9 [166] 
nicardipine BSEP (Sf9) na [123] 
nifedipine BSEP (Sf9) na [123] 
Oligomycin rat canalicular vesicles na [237, 295] 
PKI166 rat canalicular vesicles na [310] 
pravastatin BSEP (HEK293) 
BSEP (Sf9) 
dog Bsep (Sf9) 
Ki 10 
IC50 240 
IC50 441 
[124] 
[347] 
[347] 
prenylamine BSEP (Sf9) na [123] 
probenicide rat canalicular vesicles na [237] 
quinidine rat canalicular vesicles Ki 542 [134] 
reserpine BSEP (Sf9) IC50 3 [157] 
rifampicin rat canalicular vesicles Ki 6 [293] 
rifampicin rat Bsep (Sf9) 
BSEP (high five) 
BSEP (Sf9) 
dog Bsep 
Ki 12 
Ki 31 
IC50 11 
na 
[293] 
[34] 
[157] 
[347] 
rifampicin BSEP (LLC-PK1) na [221] 
rifamycin SV rat canalicular vesicles Ki 0.9 [293] 
rifamycin SV rat Bsep in Sf9 cells Ki 4 [293] 
rifamycin SV BSEP (LLC-PK1) na [221] 
ritonavir BSEP (Sf9 na [213] 
ritonavir primary human hepatocytes in 
sandwich culture 
primary rat hepatocytes in 
sandwich culture 
concentration dependent 
 
concentration dependent 
[213] 
 
[213] 
rosiglitazone rat canalicular vesicls concentration dependent [286] 
saquinavir BSEP (Sf9) na [213] 
saquinavir primary human hepatocytes in 
sandwich culture 
primary rat hepatocytes in 
sandwich culture 
concentration independent 
 
concentration dependent 
[213] 
 
[213] 
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sulfinpyrazone rat canalicular vesicls na [237] 
troglitazone rat canalicular vesicles 
rat canalicualr vesicles 
Ki 1 
concentration dependent 
[83] 
[286] 
troglitazone rat Bsep (Sf9) 
rat Bsep (Sf9) 
BSEP (Sf9) 
BSEP(Sf9) 
mouse Bsep (Sf9) 
dog Bsep (Sf9) 
IC50 60 
IC50 28 
IC 50 20 
IC50 10 
IC50 40 
IC50 32 
[347] 
[157] 
[347] 
[157] 
[157] 
[347] 
troglitazone primary rat hepatocytes in 
sandwich culture 
primary rat hepatocytes in 
sandwich culture 
primary human hepatocytes in 
sandwich culture 
concentration dependent 
 
concentration dependent 
 
concentration dependent 
[151] 
 
[210] 
 
[210] 
troglitazone sulfate rat canalicuar vesicles Ki 0.2 [83] 
troleandomycin primary human hepatocytes in 
sandwich culture 
concentration dependent [167] 
valinomycin Rat canalicular vesicles na [297] 
valinomycin BSEP(Sf9) IC50 1 [157] 
verapamil rat canalicular vesicles Ki 93 [134] 
vinblastine Rat Bsep (Sf9) 
BSEP (Sf9) 
BSEP (Sf9) 
Dog Bsep (Sf9) 
na 
na 
IC50 57 
na 
[347] 
[347] 
[157] 
[347] 
vincristine Rat Bsep (Sf9) 
BSEP (Sf9) 
Dog Bsep (Sf9) 
na 
na 
na 
[347] 
[347] 
[347] 
 
The heterologous expression system is given in parenthesis. 
na: not available 
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Table 5: 
 
Characterization of BSEP mutations in heterologous expression systems 
 
Mutation Expression 
cDNA 
Expression 
System 
Protein Targeting Protein Stability Transport Function Reference 
G238V 
E297G 
C336S 
D482G 
G982R 
R1153C 
R1268Q 
 
rBsep MDCK for 
targeting 
Sf9 cells for 
transport 
no surface expression 
no surface expression 
normal 
normal 
no surface expression 
no surface expression 
no surface expression 
rapid degradation 
na 
na 
na 
na 
na 
na 
na 
absent 
normal 
abolished 
abolished 
abolished 
abolished 
[337] 
D482G mBsep HepG2 for 
targeting 
SF21 cells for 
transport 
reduced canalicular targeting and altered 
processing 
temperature sensitive 
mRNA 
normal (slight reduction 
of ATPase activity) 
[256] 
E297G 
D482G 
BSEP MDCK for 
targeting 
HEK 293 for 
partial surface expression 
no surface expression 
shortened half live of 
membrane form 
normal 
normal 
[115] 
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targeting and 
transport 
E297G 
R432T 
BSEP Sf9 cells na 
na 
na 
na 
reduced 
reduced 
[239] 
E297G 
D482G 
A570T 
N591S 
R1050C 
rBsep MDCK for 
targeting 
HEK 293 for 
targeting 
Sf9 cells for 
transport 
reduced surface expression 
no surface expression 
reduced surface expression 
reduced surface expression 
reduced surface expression 
na 
na 
na 
na 
na 
 
absent 
normal 
normal 
normal 
normal 
[182] 
D676Y 
G855R 
BSEP Sf9 cells na na normal 
reduced 
[185] 
E297G 
K461E 
A570T 
D482G 
G982R 
R1050C 
R1153C 
R1057X 
R1286Q 
rBsep MDCK normal  
no surface expression 
normal 
reduced surface expression 
no surface expression 
normal 
no surface expression 
normal 
no surface expression 
na 
na 
na 
shortened half-life 
na 
na 
na 
na 
na 
reduced 
absent 
reduced 
reduced 
absent 
reduced 
absent 
absent 
absent 
[144] 
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3467-
8insC 
no surface expression na absent 
G238V 
D482G 
G982R 
R1153C 
R1286Q 
rBsep HEK 293 
cells 
reduced surface expression 
reduced surface expression 
no surface expression 
no surface expression 
no surface expression 
rescued by low 
temperatur and glycerol 
na 
na 
na 
na 
na 
na 
na 
na 
[336] 
E297G 
D482G 
BSEP MDCK faster turnover of ubiquitinated BSEP 
from apical membrane 
increased 
ubiquitination 
 [114] 
 
Additional information on expression of BSEP mutants is found in [30]. For an extensive characterization of BSEP expression in liver of patients with PFIC2 refer 
to [230] 
 
na: not assessed 
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